Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2000

View Archived Issues

Aquila receives SBIR grant to use CD1 technology in pursuit of Chlamydia vaccine

Atrix and Elan form partnership focused on oncology and pain management

Interim results indicate that Remune + antiviral drugs may stimulate killer T-cell activity

Panacea enters agreements with Loyola covering Lewy body disorders

BioSante signs option license agreement with ID Biomedical for vaccine delivery

First selective, irreversible N-SMase inhibitor designed by German university researchers

NitroMed and UT report phase II results of NMI-870 as treatment for female sexual dysfunction

Access to commence phase III clinical trials with OraDisc

Development of CI-1033, an irreversible inhibitor of EGF tyrosine kinase activity

CEP-1347 characterized at medicinal chemistry meeting as potential antiparkinsonian

PTK-787/ZK-222584 expected to show improved selectivity as kinase inhibitor, according to SAR

ENDO 2000: focus on cardiovascular effects of examorelin

EB-1089 as a potential agent for the management of refractory thyroid carcinoma

Sch-66336 warrants further evaluation for the treatment of glioblastoma multiforme

Eniporide now claimed to be useful in NIDDM

Lilly claims new uses for LY-203638

Selective PDE4 inhibitors with bronchodilating, antiinflammatory properties

Sanofi-Synthelabo synthesizes new compounds for GABAergic transmission-associated disorders

Dual D2 and 5-HT1A receptor partial agonists claimed for depression and anxiety

Oxazolidinone antibacterial agents from Bayer

More neuraminidase inhibitors in development at Gilead

Korean laboratory presents new and improved proton pump inhibitors

New Merck compounds selectively antagonize alpha1A-adrenoceptors

SC-744 and its active enantiomer SC-795, two new CETP inhibitors

Advantage-S study fails to demonstrate effectiveness as HIV prophylactic

Aventis receives E.U. approval for Lantus

Nutropin Depot now available

Elan receives FDA approvable letter for ziconotide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...